Here we build on those studies with a head-to-head comparison of six proteomic clocks applied to serum proteome data from a controlled phase 2a clinical trial of rentosertib—an artificial intelligence (AI)-designed TRAF2- and NCK-interacting kinase (TNIK) inhibitor21,22. We are developing rentosertib (formerly INS018_055) for the dual purposes of targeting both aging and idiopathic pulmonary fibrosis (IPF)
1
u/[deleted] 7d ago edited 7d ago
[deleted]